Filing Flows

Filing Flows › Regenxbio (RGNX) › Next earnings date

Regenxbio (RGNX) earnings: beat the estimate

Regenxbio (RGNX) reported on Nov 5, 2026 and beat the EPS estimate: −$1.21 against −$1.30 (+7.0%). Revenue was $9.2M for Q3 2026, -69% year over year. It beat the EPS estimate in 60% of the quarters on record.

Last result+7.0% vs estimate
Beat rate60%

The last report

Regenxbio reported revenue of $9.2M for the third quarter 2026 (-69% Y/Y), net loss $40.7M: License and Service $5.2M, Service $3.9M. How it makes money → · Every quarter →

Regenxbio: EPS against the estimate, last 5 reportsRegenxbio: EPS against the estimate, last 5 reportsEstimateReported−$1.30−$1.20Nov 25−$0.84−$1.30Mar 26−$1.41−$1.72May 26−$0.11$0.43Aug 26−$1.30−$1.21Nov 26
Latest (Nov 26): Estimate −$1.30, Reported −$1.21.

Regenxbio's latest quarter

Regenxbio, Q3 2026: revenue $9.2M (-69% year over year), operating margin -387.8%, net loss $40.7M, operating cash flow $38.6M. The chart follows the revenue to costs, profit and cash.

Questions

Did Regenxbio beat earnings?

Regenxbio (RGNX) reported on Nov 5, 2026 and beat the EPS estimate: −$1.21 against −$1.30 (+7.0%).

When does RGNX report earnings?

The next date is not set yet.

Does Regenxbio usually beat earnings?

It beat the consensus EPS estimate in 60% of the quarters on record.

Open the interactive view →

Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.